Top Page
China Life Insurance Co
(2628)
China Life Insurance Co (2628) vs. iShares MSCI Hong Kong ETF (EWH)
China Life Insurance Co Business Overview & Revenue Model
China Life Insurance Co Earnings Call Summary
China Life Insurance Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 377.40B | 512.20B | 396.47B | 822.30B | 848.11B | 816.68B |
| Gross Profit | 376.99B | 510.40B | 394.74B | 66.12B | 85.99B | 56.08B |
| EBITDA | 230.13B | 120.24B | 57.00B | 33.84B | 60.88B | 62.94B |
| Net Income | 109.59B | 106.94B | 51.18B | 32.08B | 50.77B | 50.26B |
Balance Sheet | ||||||
| Total Assets | 7.29T | 6.77T | 5.89T | 5.25T | 4.89T | 4.25T |
| Cash, Cash Equivalents and Short-Term Investments | 120.93B | 86.52B | 2.41T | 1.87T | 1.49T | 1.27T |
| Total Debt | 36.97B | 49.27B | 48.97B | 49.34B | 55.86B | 57.21B |
| Total Liabilities | 6.76T | 6.25T | 5.42T | 4.81T | 4.40T | 3.80T |
| Stockholders Equity | 523.62B | 509.68B | 460.11B | 436.17B | 478.58B | 450.05B |
Cash Flow | ||||||
| Free Cash Flow | 329.56B | 374.82B | 384.06B | 348.89B | 280.97B | 296.56B |
| Operating Cash Flow | 300.44B | 378.80B | 388.23B | 351.97B | 286.45B | 304.02B |
| Investing Cash Flow | -449.35B | -354.62B | -428.10B | -164.96B | -393.73B | -292.80B |
| Financing Cash Flow | 81.58B | -86.76B | 60.27B | -120.09B | 111.14B | -7.76B |
China Life Insurance Co Technical Analysis
China Life Insurance Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | HK$202.54B | 4.72 | 34.37% | 6.28% | 49.90% | 203.77% | |
83 Outperform | $1.17T | 5.89 | 28.10% | 3.62% | 17.69% | 126.41% | |
78 Outperform | $389.16B | 6.31 | 17.34% | 2.98% | 9.40% | 79.93% | |
76 Outperform | $342.36B | 5.22 | 18.41% | 3.82% | 15.08% | 23.13% | |
72 Outperform | $1.10T | 6.72 | 14.53% | 4.94% | 10.20% | 19.74% | |
71 Outperform | $65.16B | 7.97 | 10.74% | 2.01% | 23.64% | 36.32% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
China Life Insurance Co Corporate Events
China Life Insurance Co has announced the renewal of its continuing connected transactions with AMP, a subsidiary of its associate company, under a new Framework Agreement set to be finalized by December 31, 2025. This agreement will allow CLI to continue its daily transactions with AMP, including the subscription and redemption of fund products and private asset management. The transactions are subject to specific reporting and approval requirements under the Hong Kong and SSE Listing Rules, given the significant cumulative transaction amount between the involved parties.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced plans to enter a new agreement with its subsidiary, CLI, for the management of insurance fund investments. This agreement, effective from January 2026, will see CLI continue to manage assets on behalf of China Life, with the transactions categorized as continuing connected transactions under Hong Kong’s listing rules. The agreement requires independent shareholder approval due to the significant percentage ratios involved, and an extraordinary general meeting will be convened for this purpose. The new agreement aims to ensure compliance with regulatory requirements and enhance investment management services, potentially impacting the company’s operational efficiency and stakeholder interests.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited, a leading insurance provider in China, specializes in life insurance, annuity insurance, and health insurance, and is known for its extensive sales network and robust financial performance. In its third-quarter report for 2025, China Life Insurance reported significant financial growth, with total assets reaching RMB 7,417,981 million, marking a 9.6% increase from the previous year. The company’s operating income for the nine months ending September 2025 was RMB 537,895 million, a 25.9% increase compared to the same period in 2024, driven by strategic asset-liability management and enhanced equity investments. Key highlights include a 60.5% increase in net profit attributable to equity holders, reaching RMB 167,804 million, and a substantial rise in earnings per share to RMB 5.94. The company also achieved a gross investment income of RMB 368,551 million, reflecting a 41.0% year-on-year increase. Looking ahead, China Life Insurance remains committed to a customer-centric approach, focusing on business value, profitability, and long-term development strategies to sustain its growth trajectory and solidify its market position.
China Life Insurance Company Limited has reported significant financial growth in its 2025 third quarter report. The company’s total assets increased by 9.6% to RMB 7,417,981 million, and equity attributable to equity holders rose by 22.8%. Operating income saw a substantial rise of 54.8% for the quarter, with a net profit before income tax increasing by 114.3%. These results indicate a strong financial performance, reflecting positively on the company’s market position and potentially benefiting stakeholders.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has released its solvency quarterly report for the third quarter of 2025, prepared under the guidelines of the National Financial Regulatory Administration. This report reflects the company’s adherence to regulatory standards and provides insights into its financial health, which is crucial for maintaining stakeholder confidence and ensuring continued operations within the competitive insurance market in China.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced a connected transaction involving a significant capital contribution to an Equity Investment Plan established by China Life Industries. The company plans to invest RMB2,000,000,000, while China Life Industries will contribute RMB10,000,000. This investment is structured under an entrustment contract with CLI, and aims to subscribe to a limited partnership interest in the Partnership. The transaction is categorized as a connected transaction under the Listing Rules, subject to reporting and announcement requirements, but exempt from independent shareholders’ approval.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced the renewal of its framework agreement with AMP, allowing for continued daily transactions such as the subscription and redemption of fund products and private asset management. These transactions are classified as continuing connected transactions under Hong Kong’s Listing Rules, with specific exemptions from independent shareholder approval due to the applicable percentage ratios. This renewal is expected to maintain operational continuity and compliance with regulatory requirements, impacting the company’s financial dealings and strategic partnerships.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$31.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited announced that it will release its 2025 third quarter results on October 30, 2025, and will hold a results briefing on the same day to provide investors with a deeper understanding of its financial performance and business operations. The briefing will be conducted via webcast and text interaction, allowing investors to engage with the company’s senior management and ask questions, thereby enhancing transparency and communication with stakeholders.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$29.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced an estimated significant increase in net profit for the first three quarters of 2025, with expectations of a 50% to 70% rise compared to the same period in 2024. This growth is attributed to strategic asset-liability management, investment in new productive forces, and a recovering stock market, enhancing the company’s investment returns and long-term stability.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$29.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced a board meeting scheduled for October 30, 2025, to consider and approve its unaudited financial results for the first three quarters of 2025. This meeting is significant as it will provide insights into the company’s financial health and performance, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$29.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced an updated interim dividend for the first half of 2025, declaring RMB 0.238 per share, with the payment to be made in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.093446. The announcement outlines the withholding tax rates applicable to different categories of shareholders, impacting both enterprise and individual non-resident shareholders, as well as Mainland investors using the Hong Kong Stock Connect Program.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$29.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited announced that all resolutions were passed at its first extraordinary general meeting of 2025, including the distribution of an interim dividend. The meeting saw a significant turnout, with 77.5% of the total voting shares represented, reflecting strong shareholder engagement and compliance with relevant Chinese laws and regulations.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$29.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced its First Extraordinary General Meeting for 2025, scheduled for September 25, in Beijing. Key agenda items include the abolition of the Board of Supervisors, amendments to procedural rules for shareholder and board meetings, and the approval of the 2025 interim profit distribution plan. Additionally, the company has proposed amendments to its Articles of Association, reflecting its commitment to aligning with regulatory requirements. The Board has recommended an interim dividend of RMB0.238 per share, totaling approximately RMB6,727 million, to be distributed to eligible shareholders, highlighting the company’s robust financial performance and shareholder value focus.
The most recent analyst rating on (HK:2628) stock is a Buy with a HK$26.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Co. Ltd., a leading life insurance company in China, focuses on providing a range of insurance products and services, including life, health, and accident insurance, with a strong emphasis on innovation and customer-centric solutions.
China Life Insurance Company Limited announced robust unaudited interim results for the first half of 2025, marking significant growth in both business scale and quality. The company reported total assets exceeding RMB7 trillion and a net profit increase of 6.9% year-on-year, maintaining its industry leadership. It has actively contributed to national development by expanding its insurance services and investment in strategic industries, while also enhancing operational efficiency and asset-liability management to adapt to the low-interest-rate environment.
The most recent analyst rating on (HK:2628) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited released its solvency quarterly report for the second quarter of 2025, prepared in accordance with the latest regulatory standards set by the NFRA. This report reflects the company’s adherence to regulatory requirements, potentially impacting its operational transparency and stakeholder confidence.
The most recent analyst rating on (HK:2628) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced proposed amendments to its Articles of Association to enhance corporate governance and ensure compliance with relevant laws and regulatory standards. These amendments require approval from the company’s shareholders and the National Financial Regulatory Administration, and aim to align the company’s governance practices with external regulatory expectations.
The most recent analyst rating on (HK:2628) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited has announced an interim dividend of RMB 0.238 per share for the six months ending June 30, 2025, with the payment date set for November 18, 2025. The announcement outlines the withholding tax rates applicable to different categories of shareholders, which vary based on their residency and existing tax agreements with China, potentially impacting the net dividend received by investors.
The most recent analyst rating on (HK:2628) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.
China Life Insurance Company Limited announced that it will release its 2025 interim results on August 27, 2025, and will hold a briefing on August 28, 2025, to provide investors with a comprehensive understanding of the results and business operations. The briefing will be conducted via webcast and text interaction, with senior management available to address investor questions, indicating the company’s commitment to transparency and investor engagement.
The most recent analyst rating on (HK:2628) stock is a Hold with a HK$21.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.